Olfactory mucus & Anosmia
gedropi
with Anosmia & loss/change in ability to taste. These losses were
immediately preceded by a flu virus of considerable length and
severity. These are not associated with Zicam, low zinc, low B12,
smoking & some of the more typical causes as this person eats well,
supplements adequately and is in otherwise excellent health. P-r-o-b-a-
b-l-y not associated with PK or AD based upon the Smell Test of 10
values. This person is 63.
Thank you for your comments
Kofi
<ffc1a304-f8ec-44db...@h14g2000pri.googlegroups.com>,
gedropi <ged...@gmail.com> wrote:
Sounds like it could be local nerve damage involving the sympathetic
nervous system. Try a neurotransmitter test. That probably won't tell
you anything if the damage is local. Local damage in the transmission
of ATP, serotonin or the catecholamines would explain all the symptoms -
but that doesn't mean you can boost the sympathetic nervous system
globally without some problems. I don't know how to help you if it's a
parasympathetic or autonomic issue. It's a specialized nervous system
problem.
Without knowing what it is, the only thing I could suggest is a period
of intermittent fasting which would be helpful for autoimmunity,
inflammation or neurodegeneration. If the person gets sick or dizzy
during the fast, don't persist with it.
Try a high dose of vitamin D3 for a day or two and see if the senses
return. Check the vitamin D and magnesium levels.
It's possible they developed autoantibodies that only pose problems when
certain foods are eaten and these cross-react with certain nerves. If
that's the case, an allergy elimination diet could help.
There might be a secondary viral infection involved like CMV or
Epstein-Barr. Check the viral titers.
Look for any other associated symptoms, no matter how minor the
difference (e.g., a sudden disinterest in gambling, depression, so
on...).
It could just be damage to the nerves involved in smell. If so, it is
possible it might repair itself on its own. Something like carnitine or
another neurogenesis agent could accelerate the recovery.
James Geiger MD
Or prior sinus surgery I hope.....
First and foremost Vitamin A def.
then
Stimulate sense of smell with essential oils that have deep base
notes, like frankincense.
James Geiger MD
www.oilMD.com
author of The Sweet Smell of success
gedropi
> In article
> <ffc1a304-f8ec-44db-86eb-ef26d8fdf...@h14g2000pri.googlegroups.com>,
Here's one approach.
Treatment of Postviral Olfactory Loss With Glucocorticoids, Ginkgo
biloba, and Mometasone Nasal Spray
Beom Seok Seo, MD; Hyun Jong Lee, MD; Ji-Hun Mo, MD; Chul Hee Lee, MD;
Chae-Seo Rhee, MD; Jeong-Whun Kim, MD, PhD
Arch Otolaryngol Head Neck Surg. 2009;135(10):1000-1004.
Objective To analyze the efficacy of treating postviral olfactory
loss with glucocorticoids, Ginkgo biloba, and mometasone furoate nasal
spray.
Design Randomized trial.
Setting Academic research.
Patients Seventy-one patients who were diagnosed as having postviral
olfactory loss.
Main Outcome Measures All patients underwent olfactory function
tests, including the butanol threshold test (BTT) and the cross-
cultural smell identification test (CCSIT), and follow-up tests were
performed 4 weeks later. In the interim, 28 patients were treated with
prednisolone for 2 weeks (monotherapy), and the other 43 patients were
treated with prednisolone for 2 weeks plus G biloba for 4 weeks
(combination therapy). All patients used mometasone nasal spray twice
daily for 4 weeks.
Results Scores on the BTT and CCSIT significantly increased after
treatment in both groups (P < .001 for both). The mean (SD) BTT score
changes were 1.4 (2.2) in the monotherapy group and 2.2 (2.9) in the
combination therapy group (P = .22). The mean (SD) CCSIT score changes
were 0.9 (1.7) in the monotherapy group and 1.9 (2.7) in the
combination therapy group (P = .11). On the BTT, the treatment
response (defined as a score increase of ≥3) rates were 32% (9 of 28)
in the monotherapy group and 37% (16 of 43) in the combination therapy
group (P = .66), and the odds ratio was 1.25 (95% confidence interval,
0.46-3.42). On the CCSIT, the treatment response rates were 14% (4 of
28) in the monotherapy group and 33% (14 of 43) in the combination
therapy group (P = .08), and the odds ratio was 2.89 (95% confidence
interval, 0.84-9.97).
Conclusions Olfactory function in patients with postviral olfactory
loss was significantly improved by both treatment modalities. Although
the treatment response was not statistically different between the
monotherapy group and the combination therapy group, the addition of G
biloba showed a tendency of greater efficacy in the treatment of
postviral olfactory loss.